Claims

1. A camsylate salt of (1r,1'R,4R)- 4-methoxy-5''-methyl-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2''-imidazol]-4''-amine:



2. A camsylate salt of (1r,1'R,4R)- 4-methoxy-5''-methyl-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2''-imidazol]-4''-amine:



characterized in that said camsylate salt has an X-ray powder diffraction (XRPD) pattern, exhibiting substantially the following very strong, strong and medium peaks with d-values:

Corrected Angles	d-spacing (Å)	Relative intensity
5.66	15.60	vs
7.72	11.44	m
11.30	7.83	m
12.35	7.16	s
12.83	6.89	m
15.24	5.81	m
15.47	5.72	m
17.17	5.16	m
18.13	4.89	m
19.71	4.50	m

20.77	4.27	m
21.12	4.20	m
23.63	3.76	m
24.50	3.63	m
26.18	3.40	m
26.54	3.36	m
34.30	2.61	m
36.78	2.44	m .

3. A camsylate salt of (1r,1'R,4R)- 4-methoxy-5''-methyl-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2''-imidazol]-4''-amine:



characterized in that said camsylate salt has an X-ray powder diffraction pattern essentially as shown in Figure 1.

4. A pharmaceutical composition comprising as active ingredient a therapeutically effective amount of a salt according to claim 1, 2 or 3, in association with at least one pharmaceutically acceptable excipient, carrier or diluent.

5. A salt according to claim 1, 2 or 3 for use as a medicament.

6. A salt according to claim 5, for use as a medicament for treating or preventing an Aβ-related pathology.

7. A salt according to claim 6, for use as a medicament for treating or preventing an Aβ-related pathology, wherein said Aβ-related pathology is Down's syndrome, a β-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer's

Disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with Alzheimer's Disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

8. A salt according to claim 7, for use as a medicament for treating or preventing Alzheimer's Disease.

9. A salt according to claim 1, 2 or 3, for use as a medicament for treating or preventing an Aβ-related pathology in combination with at least one cognitive enhancing agent, memory enhancing agent, or choline esterase inhibitor.

10. Use of a therapeutically effective amount of a salt according to claim 1, 2 or 3 in the manufacture of a medicament for treating or preventing an Aβ-related pathology in a patient in need thereof.

11. The use of claim 10, wherein said Aβ-related pathology is Down's syndrome, a β-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer's Disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with Alzheimer's disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

12. Use of a therapeutically effective amount of a salt according to claim 1, 2 or 3 in the manufacture of a medicament for treating or preventing Alzheimer's Disease in a patient in need thereof.

13. Use of a therapeutically effective amount of a salt according to claim 1, 2 or 3 in the manufacture of a medicament for treating or preventing an Aβ-related pathology in a patient in need thereof, wherein said salt is used in combination with at least one cognitive enhancing agent, memory enhancing agent, or choline esterase inhibitor.

Claims

1. A camsylate salt of (1r,1'R,4R)- 4-methoxy-5''-methyl-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2''-imidazol]-4''-amine:



2. A camsylate salt of (1r,1'R,4R)- 4-methoxy-5''-methyl-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2''-imidazol]-4''-amine:



characterized in that said camsylate salt has an X-ray powder diffraction (XRPD) pattern, exhibiting substantially the following very strong, strong and medium peaks with d-values:

Corrected Angles	d-spacing (Å)	Relative intensity
5.66	15.60	vs
7.72	11.44	m
11.30	7.83	m
12.35	7.16	s
12.83	6.89	m
15.24	5.81	m
15.47	5.72	m
17.17	5.16	m

18.13	4.89	m
19.71	4.50	m
20.77	4.27	m
21.12	4.20	m
23.63	3.76	m
24.50	3.63	m
26.18	3.40	m
26.54	3.36	m
34.30	2.61	m
36.78	2.44	m .

3. A camsylate salt of (1r,1'R,4R)- 4-methoxy-5''-methyl-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2''-imidazol]-4''-amine:



characterized in that said camsylate salt has an X-ray powder diffraction pattern essentially as shown in Figure 1.

4. A pharmaceutical composition comprising as active ingredient a therapeutically effective amount of a salt according to claim 1, 2 or 3, in association with at least one pharmaceutically acceptable excipient, carrier or diluent.

5. A salt according to claim 1, 2 or 3 for use as a medicament.

6. A salt according to claim 5, for use as a medicament for treating or preventing an Aβ-related pathology.

7. A salt according to claim 6, for use as a medicament for treating or preventing an Aβ-related pathology, wherein said Aβ-related pathology is Down's syndrome, a β-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer's Disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with Alzheimer's Disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

8. A salt according to claim 7, for use as a medicament for treating or preventing Alzheimer's Disease.

9. A salt according to claim 1, 2 or 3, for use as a medicament for treating or preventing an Aβ-related pathology in combination with at least one cognitive enhancing agent, memory enhancing agent, or choline esterase inhibitor.

10. Use of a therapeutically effective amount of a salt according to claim 1, 2 or 3 in the manufacture of a medicament for treating or preventing an Aβ-related pathology in a patient in need thereof, wherein said Aβ-related pathology is Down's syndrome, a β-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with Alzheimer's disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

11. Use of a therapeutically effective amount of a salt according to claim 1, 2 or 3 in the manufacture of a medicament for treating or preventing Alzheimer's Disease in a patient in need thereof.

12. Use of a therapeutically effective amount of a salt according to claim 1, 2 or 3 in the manufacture of a medicament for treating or preventing an Aβ-related pathology in a patient in need thereof, wherein said salt is used in combination with at least one cognitive enhancing agent, memory enhancing agent, or choline esterase inhibitor, and wherein said Aβ-related pathology is Down's syndrome, a β-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with Alzheimer's disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.